Lupin has received approval for its Tadalafil tablets USP, 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company's Adcirca tablets, 20 mg.
The company's Tadalafil tablets USP, 20 mg is the generic version of Eli Lilly and Company's Adcirca tablets, 20 mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Tadalafil tablets, 20 mg (RLD: Adcirca) had annual sales of approximately $474.3 million in the US (IQVIA MAT December 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
